Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

Related Citations for PubMed (Select 23629015)

1.

Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes.

Anta L, Blanco JL, Llibre JM, García F, Pérez-Elías MJ, Aguilera A, Pérez-Romero P, Caballero E, Vidal C, Cañizares A, Gutiérrez F, Dalmau D, Iribarren JA, Soriano V, de Mendoza C; Drug Resistance Platform of the Spanish AIDS Research Network.

J Antimicrob Chemother. 2013 Sep;68(9):1994-2002. doi: 10.1093/jac/dkt146. Epub 2013 Apr 29.

2.

Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.

Santoro MM, Alteri C, Ronga L, Flandre P, Fabeni L, Mercurio F, D'Arrigo R, Gori C, Palamara G, Bertoli A, Forbici F, Salpini R, Boumis E, Tozzi V, Visco-Comandini U, Zaccarelli M, Van Houtte M, Pattery T, Narciso P, Antinori A, Ceccherini-Silberstein F, Perno CF.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1285-93. Epub 2012 Apr 18.

3.

Prevalence and resistance mutations of non-B HIV-1 subtypes among immigrants in Southern Spain along the decade 2000-2010.

de Felipe B, Pérez-Romero P, Abad-Fernández M, Fernandez-Cuenca F, Martinez-Fernandez FJ, Trastoy M, Mata Rdel C, López-Cortés LF, Leal M, Viciana P, Vallejo A.

Virol J. 2011 Aug 26;8:416. doi: 10.1186/1743-422X-8-416.

4.

Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B.

Fofana DB, Soulie C, Maiga AI, Fourati S, Malet I, Wirden M, Tounkara A, Traore HA, Calvez V, Marcelin AG, Lambert-Niclot S.

J Antimicrob Chemother. 2013 Nov;68(11):2515-20. doi: 10.1093/jac/dkt251. Epub 2013 Jul 5.

5.

Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.

Puig T, Pérez-Olmeda M, Rubio A, Ruiz L, Briones C, Franco JM, Gómez-Cano M, Stuyver L, Zamora L, Alvarez C, Leal M, Clotet B, Soriano V.

AIDS. 2000 Apr 14;14(6):727-32.

PMID:
10807196
6.

The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)-infected individuals in Casablanca, Morocco.

Bakhouch K, Oulad-Lahcen A, Bensghir R, Blaghen M, Elfilali KM, Ezzikouri S, Abidi O, Hassar M, Wakrim L.

J Infect Dev Ctries. 2009 Jun 1;3(5):380-91.

7.

The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.

van de Vijver DA, Wensing AM, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA.

J Acquir Immune Defic Syndr. 2006 Mar;41(3):352-60.

PMID:
16540937
8.

Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain.

De Mendoza C, Garrido C, Poveda E, Corral A, Zahonero N, Treviño A, Anta L, Soriano V.

AIDS Res Hum Retroviruses. 2009 Oct;25(10):967-72. doi: 10.1089/aid.2008.0166.

PMID:
19842792
9.

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.

Lambert-Niclot S, Charpentier C, Storto A, Fofana DB, Soulié C, Fourati S, Visseaux B, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG.

J Antimicrob Chemother. 2013 Jun;68(6):1237-42. doi: 10.1093/jac/dkt003. Epub 2013 Jan 29.

10.

[Rate of genotypic mutations and resistance to antiretroviral drugs in a general hospital].

Fernández Lisón LC, Fernández Pereira LM, Romero Chala S.

Farm Hosp. 2011 Jul-Aug;35(4):191-6. doi: 10.1016/j.farma.2010.05.008. Epub 2010 Nov 18. Spanish.

PMID:
21087876
11.

Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients.

Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, Reynes J, Delaporte E.

J Clin Microbiol. 2000 Nov;38(11):3919-25.

12.

Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.

Bracciale L, Colafigli M, Zazzi M, Corsi P, Meraviglia P, Micheli V, Maserati R, Gianotti N, Penco G, Setti M, Di Giambenedetto S, Butini L, Vivarelli A, Trezzi M, De Luca A.

J Antimicrob Chemother. 2009 Sep;64(3):607-15. doi: 10.1093/jac/dkp246. Epub 2009 Jul 16.

13.

Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.

Chaplin B, Eisen G, Idoko J, Onwujekwe D, Idigbe E, Adewole I, Gashau W, Meloni S, Sarr AD, Sankalé JL, Ekong E, Murphy RL, Kanki P.

AIDS Res Hum Retroviruses. 2011 Jan;27(1):71-80. doi: 10.1089/aid.2010.0050. Epub 2010 Oct 21.

14.

HIV-1 drug resistance in newly infected individuals.

Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N, Markowitz M.

JAMA. 1999 Sep 22-29;282(12):1135-41.

PMID:
10501116
15.

Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel.

Turner D, Shahar E, Katchman E, Kedem E, Matus N, Katzir M, Hassoun G, Pollack S, Kessner R, Wainberg MA, Avidor B.

J Med Virol. 2009 Sep;81(9):1509-12. doi: 10.1002/jmv.21567.

PMID:
19626612
16.

Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.

Poveda E, de Mendoza C, Parkin N, Choe S, García-Gasco P, Corral A, Soriano V.

AIDS. 2008 Mar 12;22(5):611-6. doi: 10.1097/QAD.0b013e3282f51eb9.

PMID:
18317002
17.

Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria.

Santoro MM, Ciccozzi M, Alteri C, Montieri S, Alexiev I, Dimova I, Ceccherini-Silberstein F, Beshkov D, Rezza G, Perno CF.

AIDS Res Hum Retroviruses. 2008 Sep;24(9):1133-8. doi: 10.1089/aid.2008.0042.

18.

Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy.

Brindeiro PA, Brindeiro RM, Mortensen C, Hertogs K, De Vroey V, Rubini NP, Sion FS, De Sá CA, Machado DM, Succi RC, Tanuri A.

J Clin Microbiol. 2002 Dec;40(12):4512-9.

19.

Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.

Bunupuradah T, Ananworanich J, Chetchotisakd P, Kantipong P, Jirajariyavej S, Sirivichayakul S, Munsakul W, Prasithsirikul W, Sungkanuparph S, Bowonwattanuwong C, Klinbuayaem V, Petoumenos K, Hirschel B, Bhakeecheep S, Ruxrungtham K.

Antivir Ther. 2011;16(7):1113-21. doi: 10.3851/IMP1906.

PMID:
22024527
20.

Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates.

García-Guerrero J, Sáiz de la Hoya P, Portilla J, Marco A, Sánchez-Payá J, Moreno S; Estudio de Resistencias en Prisiones Group.

Eur J Clin Microbiol Infect Dis. 2006 Nov;25(11):695-701.

PMID:
17043836
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk